A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Latest Information Update: 28 Jun 2024
At a glance
- Drugs Dordaviprone (Primary) ; Paxalisib (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Therapeutic Use
- Acronyms PNOC022
- 27 Jun 2024 According to a Kazia Therapeutics media release, company announced the presentation of data from the Phase 2 PNOC DMG-ACT at the upcoming 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) June 29 to July 2, 2024, in Philadelphia.
- 07 Jun 2024 Planned number of patients changed from 324 to 360.
- 07 Jun 2024 Planned End Date changed from 30 Jun 2027 to 30 Jun 2029.